Apellis

AstraZeneca's Alexion hopes to extend dominance in PNH as Big Pharma competitors close in
Fierce Biotech
Fri, 12/16/22 - 10:47 am
AstraZeneca
Alexion
PNH
Ultomiris
Soliris
Roche
Apellis
Novartis
Apellis plots pegcetacoplan FDA filing in blockbuster GA use after revealing 18-month data
Fierce Pharma
Wed, 03/16/22 - 10:37 am
Apellis
pegcetacoplan
geographic atrophy
FDA
Go or no go? Apellis and Heron head for the finish line
EP Vantage
Fri, 04/30/21 - 10:30 am
Apellis
anemia
pegcetacoplan
Heron Therapeutics
HTX-011
FDA
Apellis takes the complement fight to Astrazeneca
EP Vantage
Fri, 01/22/21 - 10:30 am
Apellis
Alexion
AstraZeneca
PNH
Apellis' Soliris rival gets a date at the FDA for a rare blood disorder, with potentially $400M worth of implications
Endpoints
Mon, 11/16/20 - 10:39 pm
Apellis
pegcetacoplan
PNH
As CEO bounces back from Covid-19, Apellis says FDA meeting clears path to file for an OK on Soliris rival
Endpoints
Thu, 05/21/20 - 10:31 am
Apellis
FDA
PNH
pegcetacoplan
COVID-19
Apellis touts new data for eye drug hopeful
Biopharma Dive
Sun, 02/25/18 - 11:22 am
Apellis
eye health
APL-2
age-related macular degeneration
Prepping PhIII for Soliris rival, Apellis rides a boisterous market to a $150M IPO
Endpoints
Sat, 11/11/17 - 10:59 am
Soliris
Apellis